Health Care [ 8/12 ] | Health Care Equipment & Supplies [ 51/74 ]
NASDAQ | Common Stock
PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States.
The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck.
Its product pipeline also comprises EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform.
The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015.
PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 12, 25 | -0.07 Increased by +97.33% | -0.29 Increased by +75.86% |
| Mar 24, 25 | -0.19 Increased by +89.50% | -0.40 Increased by +52.50% |
| Nov 13, 24 | -0.54 Decreased by -237.50% | 1.97 Decreased by -127.41% |
| Aug 12, 24 | -1.19 Decreased by -750.00% | -1.45 Increased by +17.93% |
| May 13, 24 | -2.62 Decreased by -1.28 K% | -1.67 Decreased by -56.89% |
| Mar 25, 24 | -1.81 Decreased by -686.96% | -1.89 Increased by +4.23% |
| Nov 13, 23 | -0.16 Increased by +44.83% | -0.14 Decreased by -14.29% |
| Aug 14, 23 | -0.14 Increased by +51.72% | -0.19 Increased by +26.32% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 8.00 M Increased by +692.08% | 17.70 B Increased by +116.42 K% | Increased by +221.19 K% Increased by +14.79 K% |
| Dec 31, 24 | 10.00 K Decreased by -99.05% | 1.43 M Increased by +110.20% | Increased by +14.31 K% Increased by +1.17 K% |
| Sep 30, 24 | 996.00 K Increased by +25.92% | 64.40 M Increased by +464.43% | Increased by +6.47 K% Increased by +389.42% |
| Jun 30, 24 | 979.00 K Increased by +489.76% | -10.83 M Increased by +25.52% | Decreased by -1.11 K% Increased by +87.37% |
| Mar 31, 24 | 1.01 M Increased by +126.46% | -15.21 M Decreased by -100.36% | Decreased by -1.51 K% Decreased by -100.16% |
| Dec 31, 23 | 1.05 M Increased by +836.61% | -14.04 M Increased by +31.63% | Decreased by -1.34 K% Increased by +92.70% |
| Sep 30, 23 | 791.00 K Increased by +940.79% | -17.67 M Increased by +32.36% | Decreased by -2.23 K% Increased by +93.50% |
| Jun 30, 23 | 166.00 K Increased by +N/A% | -14.54 M Increased by +43.05% | Decreased by -8.76 K% Decreased by N/A% |